Descrição

Inhalers are used to treat chronic obstructive pulmonary disease (COPD), such as asthma, by delivering bronchodilator medication to the airway directly, without passing through the blood. A smart inhaler is an inhaler that integrates connectivity with a mobile app, via Bluetooth, for instance. These devices are built with sensor technology that helps record data about the time and date of use, and the location of the patient at each use. According to StrategyHelix, the global smart inhalers market is expected to increase by US$ 536.4 milhões durante 2022-2028, expanding at a CAGR of 21.7% durante o período de previsão.

O relatório fornece dados atualizados sobre o tamanho do mercado para o período 2018-2021 e previsão para 2028 covering key market aspects like sales value for smart inhalers. The global smart inhalers market is segmented on the basis of product, disorder, and region. Baseado no produto, the global smart inhalers market is categorized into dry powder inhaler (DPI)-based smart inhalers , metered-dose inhaler (MDI)-based smart inhalers. Globally, the MDI-based smart inhalers segment made up the largest share of the smart inhalers market. On the basis of disorder, the global smart inhalers market has been segmented into asthma, chronic obstructive pulmonary disease (COPD). The asthma segment captured the largest share of the market in 2021. Geographically, the global smart inhalers market is segmented into Asia Pacific, Europa, América do Norte, Rest of the World (RoW). According to the research, Europe had the largest share in the global smart inhalers market.

The global smart inhalers market is highly competitive. The leading players in the smart inhalers market include AstraZeneca plc, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc (GSK), Heitkamp & Thumann KG, Novartis International AG, OPKO Health Inc. (OPK), Teva Pharmaceutical Industries Ltd., Vectura Group plc.

O relatório é um recurso inestimável para empresas e organizações ativas neste setor. It provides a cohesive picture of the smart inhalers market to help drive informed decision making for industry executives, decisores políticos, acadêmico, e analistas.

Escopo do relatório

produtos: dry powder inhaler (DPI)-based smart inhalers , metered-dose inhaler (MDI)-based smart inhalers
Disorder: asthma, chronic obstructive pulmonary disease (COPD)
Região: Ásia-Pacífico, Europa, América do Norte, Rest of the World (RoW)
Anos considerados: este relatório cobre o período 2018 para 2028

Principais benefícios para as partes interessadas

– Get a comprehensive picture of the global smart inhalers market
– Identifique setores de crescimento e tendências para investimento

Índice

Papel 1. Introdução
– Escopo do estudo
– Período de estudos
– Escopo geográfico
– Metodologia de Pesquisa
Papel 2. Smart inhalers market overview
Papel 3. Divisão de mercado por produto
– Dry powder inhaler (DPI)-based smart inhalers
– Metered-dose inhaler (MDI)-based smart inhalers
Papel 4. Market breakdown by disorder
– Asthma
– Chronic obstructive pulmonary disease (COPD)
Papel 5. Market breakdown by region
– Ásia-Pacífico
– Europa
– América do Norte
– Rest of the World (RoW)
Papel 6. Principais empresas
– AstraZeneca plc
– Boehringer Ingelheim International GmbH
– GlaxoSmithKline plc (GSK)
– Heitkamp & Thumann KG
– Novartis International AG
– OPKO Health, Inc.. (OPK)
– Teva Pharmaceutical Industries Ltd.
– Vectura Group plc
Sobre StrategyHelix
Isenção de responsabilidade